Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs
Aizhou Wang,Rafaela V P Ribeiro,Aadil Ali,Edson Brambate,Etienne Abdelnour-Berchtold,Vinicius Michaelsen,Yu Zhang,Peter Rahfeld,Haisle Moon,Hemant Gokhale,Anajara Gazzalle,Prodipto Pal,Mingyao Liu,Thomas K Waddell,Christine Cserti-Gazdewich,Kathryn Tinckam,Jayachandran N Kizhakkedathu,Lori West,Shaf Keshavjee,Stephen G Withers,Marcelo Cypel,Rafaela V. P. Ribeiro,Thomas K. Waddell,Jayachandran N. Kizhakkedathu,Stephen G. Withers
DOI: https://doi.org/10.1126/scitranslmed.abm7190
IF: 17.1
2022-02-16
Science Translational Medicine
Abstract:Donor organ allocation is dependent on ABO matching, restricting the opportunity for some patients to receive a life-saving transplant. The enzymes FpGalNAc deacetylase and FpGalactosaminidase, used in combination, have been described to effectively convert group A (ABO-A) red blood cells (RBCs) to group O (ABO-O). Here, we study the safety and preclinical efficacy of using these enzymes to remove A antigen (A-Ag) from human donor lungs using ex vivo lung perfusion (EVLP). First, the ability of these enzymes to remove A-Ag in organ perfusate solutions was examined on five human ABO-A1 RBC samples and three human aortae after static incubation. The enzymes removed greater than 99 and 90% A-Ag from RBCs and aortae, respectively, at concentrations as low as 1 μg/ml. Eight ABO-A1 human lungs were then treated by EVLP. Baseline analyses of A-Ag in lungs revealed expression predominantly in the endothelial and epithelial cells. EVLP of lungs with enzyme-containing perfusate removed over 97% of endothelial A-Ag within 4 hours. No treatment-related acute lung toxicity was observed. An ABO-incompatible transplant was then simulated with an ex vivo model of antibody-mediated rejection using ABO-O plasma as the surrogate for the recipient circulation using three donor lungs. The treatment of donor lungs minimized antibody binding, complement deposition, and antibody-mediated injury as compared with control lungs. These results show that depletion of donor lung A-Ag can be achieved with EVLP treatment. This strategy has the potential to expand ABO-incompatible lung transplantation and lead to improvements in fairness of organ allocation.
cell biology,medicine, research & experimental